Cannabis for diabetes control
I still haven't found the primary physician reference I'm seeking on this, but I'm beginning to think the regimen is 50 mg of THCv every 8 hours. That's a cannabinoid that can be difficult to find in quantity. Hmmm.... I'll keep looking.
At one point I thought it was 50 mg of THC, but few could tolerate that dose in a regular basis. 200 mg a day of THC is more than most would be comfortable with. I wonder if she meant THCa? That would make sense too. Ahhh, the mysteries we get to search through.
Now, the challenge is growing a plant high in THCv.
Clinical Trial: THCv lowers blood sugar levels in type-2 diabetics
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
Jadoon KA, et al. Diabetes Care. 2016.
Abstract
OBJECTIVE: Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS: In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. The primary end point was a change in HDL-cholesterol concentrations from baseline. Secondary/tertiary end points included changes in glycemic control, lipid profile, insulin sensitivity, body weight, liver triglyceride content, adipose tissue distribution, appetite, markers of inflammation, markers of vascular function, gut hormones, circulating endocannabinoids, and adipokine concentrations. Safety and tolerability end points were also evaluated.
RESULTS: Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = -1.2 mmol/L; P < 0.05) and improved pancreatic β-cell function (HOMA2 β-cell function [ETD = -44.51 points; P < 0.01]), adiponectin (ETD = -5.9 × 10(6) pg/mL; P < 0.01), and apolipoprotein A (ETD = -6.02 μmol/L; P < 0.05), although plasma HDL was unaffected. Compared with baseline (but not placebo), CBD decreased resistin (-898 pg/ml; P < 0.05) and increased glucose-dependent insulinotropic peptide (21.9 pg/ml; P < 0.05). None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated.
CONCLUSIONS: THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.
. 2016 by the American Diabetes Association.
I have diabetes I really want to learn how to make oil maybe I can try it with some of my outdoor fall harvest if all goes well